Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

被引:0
|
作者
Cashin, Peter Harald [1 ]
Asplund, Dan [2 ,6 ]
Lindskog, Elinor Bexe [2 ]
Ghanipour, Lana [1 ]
Syk, Ingvar [3 ]
Graf, Wilhelm [1 ]
Nilsson, Per J. [4 ,5 ]
Palmer, Gabriella Jansson [4 ,5 ]
机构
[1] Uppsala Univ Hosp, Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Skanes Univ Hosp, Malmo, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden
关键词
Colorectal cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Relapse treatment; Systemic chemotherapy; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MULTICENTER; PROGNOSIS; CANCERS;
D O I
10.1016/j.sopen.2024.05.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated. Objectives: To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease. Methods: Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated. Results: Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30-58) in the interventional group and 19 months (95%CI: 15-24) in the palliative group (HR 0.35 95%CI: 0.20-0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38-45). Conclusion: After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [41] Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience
    Alzahrani, Nayef A.
    Valle, Sarah J.
    Fisher, Oliver M.
    Sugarbaker, Paul H.
    Yonemura, Yutaka
    Glehen, Olivier
    Goere, Dianne
    Honore, Charles
    Brigand, Cecile
    de Hingh, Ignace
    Verwaal, Vic J.
    Deraco, Marcello
    Baratti, Dario
    Kusamura, Shigeki
    Pocard, Mark
    Piso, Pompiliu
    Maerz, Loreen
    Marchal, Frederic
    Moran, Brendan
    Levine, Edward A.
    Dumont, Frederic
    Pezet, Denis
    Abboud, Karine
    Kozman, Mathew A.
    Liauw, Winston
    Morris, David L.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 119 (03) : 336 - 346
  • [42] Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?
    Baratti, Dario
    Kusamura, Shigeki
    Iusco, Domenico
    Cotsoglou, Christian
    Guaglio, Marcello
    Battaglia, Luigi
    Virzi, Salvatore
    Mazzaferro, Vincenzo
    Deraco, Marcello
    DISEASES OF THE COLON & RECTUM, 2018, 61 (09) : 1026 - 1034
  • [43] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience
    Ingmar Königsrainer
    Philipp Horvath
    Florian Struller
    Eva Maria Grischke
    Diethelm Wallwiener
    Alfred Königsrainer
    Stefan Beckert
    Langenbeck's Archives of Surgery, 2014, 399 : 589 - 594
  • [44] The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases
    van der Werf, L. R.
    Wassenaar, E.
    de Niet, A.
    Lalezari, F.
    Braam, H. J.
    van Ramshorst, B.
    Nederend, J.
    de Hingh, I. H. J. T.
    Kok, N. F. M.
    Aalbers, A. G. J.
    EJSO, 2019, 45 (03): : 376 - 382
  • [45] Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer
    Piso, Pompiliu
    Stierstorfer, Kathrin
    Gerken, Michael
    Klinkhammer-Schalke, Monika
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (11) : 1559 - 1567
  • [46] Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Dietz, Michelle V.
    Hannink, Gerjon
    Said, Ibrahim
    van der Zant, Femke A.
    van de Vlasakker, Vincent C. J.
    Brandt-Kerkhof, Alexandra R. M.
    Verhoef, Cornelis
    Bremers, Andreas J. A.
    de Wilt, Johannes H. W.
    Hemmer, Patrick H. J.
    de Hingh, Ignace H. J. T.
    de Reuver, Philip R.
    Madsen, Eva V. E.
    EJSO, 2024, 50 (06):
  • [47] Recurrence and Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Synchronous and Metachronous Peritoneal Metastases of Colorectal Origin
    Nielsen, Mette Fugleberg
    Ravn, Sissel
    Sorensen, Mette Moller
    Funder, Jonas Amstrup
    Iversen, Lene Hjerrild
    CANCERS, 2024, 16 (03)
  • [48] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era
    Michael Eamon Kelly
    Edward Murphy
    Alan Martin Keyes
    Mohammad Faraz Khan
    Jarlath C. Bolger
    Josh Grundy
    John Conneely
    John MacHale
    John McCaffrey
    Ronan Cahill
    Brendan Moran
    Conor Shields
    Jürgen Mulsow
    Irish Journal of Medical Science (1971 -), 2021, 190 : 1373 - 1377
  • [49] Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Cashin, Peter H.
    Graf, Wilhelm
    Nygren, Peter
    Mahteme, Haile
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (13) : 4183 - 4189
  • [50] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre
    Flood, Michael P.
    Narasimhan, Vignesh
    Waters, Peadar S.
    Kong, Joseph C.
    Ramsay, Robert
    Michael, Michael
    Tie, Jeanne
    McCormick, Jacob J.
    Warrier, Satish K.
    Heriot, Alexander G.
    ANZ JOURNAL OF SURGERY, 2022, 92 (09) : 2192 - 2198